Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rifapentine
Drug ID BADD_D01937
Description Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Indications and Usage For the treatment of pulmonary tuberculosis.
Marketing Status approved; investigational
ATC Code J04AB05
DrugBank ID DB01201
KEGG ID D00879
MeSH ID C018421
PubChem ID 135403821
TTD Drug ID D0G9IU
NDC Product Code 40074-0009; 0088-2102; 50090-5063; 68022-7055; 53002-1718
UNII XJM390A33U
Synonyms rifapentine | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV | DL 473-IT | Rifapex | Priftin | DL 473 | DL-4-73 | MDL 473
Chemical Information
Molecular Formula C47H64N4O12
CAS Registry Number 61379-65-5
SMILES CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C) OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C6CCCC6)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Smear cervix abnormal13.20.02.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Sputum increased22.02.03.007--Not Available
Stupor19.02.05.004; 17.02.04.007--Not Available
Suicidal ideation19.12.01.003--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytosis01.08.02.001--Not Available
Thrombophlebitis24.01.02.001--Not Available
Thrombosis24.01.01.006--Not Available
Tooth disorder07.09.05.001--Not Available
Torticollis17.01.03.003; 15.05.04.003--Not Available
Tremor17.01.06.002--
Tuberculosis11.04.01.006--Not Available
Tympanic membrane perforation12.01.14.001; 04.05.04.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vascular purpura23.06.01.008; 24.07.06.011; 01.01.04.007--Not Available
Viral infection11.05.04.001--Not Available
Vomiting07.01.07.0030.004519%
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages